Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Dermata Therapeutics

Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata to Present at the H.C. Wainwright Global Investment Conference
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Dermata Therapeutics
Via AccessWire
Exposures Product Safety
Tickers DRMA DRMAW
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Dermata Therapeutics
Via AccessWire
Tickers DRMA DRMAW
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Dermata Therapeutics
Via AccessWire
Tickers DRMA DRMAW
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
From Dermata Therapeutics
Via AccessWire
Tickers DRMA DRMAW
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata to Present at the H.C. Wainwright BioConnect Conference
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering
Exposures Product Safety Securities Market
Tickers DRMA DRMAW
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
From Dermata Therapeutics
Via AccessWire
Tickers DRMA
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering Intellectual Property
Exposures Intellectual Property Product Safety Securities Market
Tickers DRMA
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
From Dermata Therapeutics
Via AccessWire
Tickers DRMA DRMAW
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
From Dermata Therapeutics
Via AccessWire
Tickers DRMA DRMAW
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
From Dermata Therapeutics
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers DRMA DRMAW
Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
From Dermata Therapeutics
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Tickers DRMA DRMAW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.